Tracking these meetings provides early indication of likely outcomes
This makes acquiring retatrutide through official channels virtually impossible for the average consumer
A few other states are planning or considering obesity drug restrictions in state fiscal year 2026 or 2027, and state interest in expanding coverage of obesity drugs is also waning according to this years survey, with states continuing to report cost as the key factor contributing to obesity drug coverage decisions
Monitor for signs of inadequate disease control, such as elevated blood glucose readings, increased thirst, frequent urination, or unexplained weight changes
Clinically, GLP-1 agonists appear to have a broadly beneficial impact on cancer prevention as supported by this report
Ontario covers Ozempic through the Ontario Drug Benefit program for eligible recipients with type 2 diabetes, but weight loss without diabetes does not qualify for coverage